Skip to main content
. Author manuscript; available in PMC: 2015 Jun 24.
Published in final edited form as: J Nucl Med. 2013 Apr 24;54(6):977–983. doi: 10.2967/jnumed.112.112979

FIGURE 1.

FIGURE 1

Tissue-engineering in vitro model system. (A) Fibrin-encapsulated TGF-β1–conditioned human MSCs are seeded over in vitro cardiac constructs. (B) Acellular fibrin gel is used as control. Tissue sections show immunofluorescent staining for troponin (green), caspase-3 (red), and nuclei 4′,6-diamidino-2-phenylindole (blue for nuclei), after 1 and 7 d of in vitro culture under hypoxic conditions (5% oxygen). Arrow points to engrafted TGF-β1–conditioned MSCs. There is less caspase-3 staining (therefore less apoptosis) in cardiac constructs treated with TGF-β1–conditioned human MSC fibrin than in control group at both time points. (C) Caspase-3–positive cells (5-μm section) in in vitro constructs treated with acellular patches (bar on left) or TGF-β1–conditioned MSC patches (bar on right). (D) H&E-stained section of MSCs in CP delivery patch for in vivo experiments. DAPI = 4′,6-diamidino-2-phenylindole; Tnl = troponin.